Objective: Oxidative stress and mitochondrial dysfunction are implicated in polycystic ovary syndrome (PCOS). The present study assesses the effect of metformin treatment on mitochondrial function in polymorphonuclear cells from PCOS subjects. Additionally, we evaluate endocrine parameters and levels of interleukin 6 (IL6) and tumour necrosis factor alpha (TNFa). Design and methods: Our study population was comprised of 35 women of reproductive age diagnosed with PCOS and treated with metformin for 12 weeks, and their corresponding controls (nZ41), adjusted by age and BMI. We evaluated the alteration of endocrinological and anthropometrical parameters and androgen levels. Mitochondrial O 2 consumption (using a Clark-type O 2 electrode), membrane potential, mitochondrial mass, and levels of reactive oxygen species (ROS) and glutathione (GSH) (by means of fluorescence microscopy) were assessed in poymorphonuclear cells. H 2 O 2 was evaluated with the Amplex Red R H 2 O 2 /Peroxidase Assay kit. IL6 and TNFa were measured using the Luminex 200 flow analyser system.Results: Metformin had beneficial effects on patients by increasing mitochondrial O 2 consumption, membrane potential, mitochondrial mass and glutathione levels, and by decreasing levels of reactive oxygen species and H 2 O 2 . In addition, metformin reduced glucose, follicle-stimulating hormone, IL6 and TNFa levels and increased dehydroepiandrosterone sulfate levels. HOMA-IR and mitochondrial function biomarkers positively correlated with ROS production (rZ0.486, PZ0.025), GSH content (rZ0.710, PZ0.049) and H 2 O 2 (rZ0.837, PZ0.010), and negatively correlated with membrane potential (rZK0.829, PZ0.011) at baseline. These differences disappeared after metformin treatment.Conclusions: Our results demonstrate the beneficial effects of metformin treatment on mitochondrial function in leukocytes of PCOS patients.